News
Videos
Conferences
Events
Resources
Subscribe

|Videos|September 27, 2017

Improving Outcomes in Bladder Cancer

Newsletter

Stay up to date on cancer updates, research and education

Related Content

leading oncology experts

Cancer Experts Share Emerging Treatments Patients Should Know in 2026

November 12th 2025

Trial data showed a 62% complete response rate at 6 months with detalimogene coraplasmid among patients with high-risk, BCG-unresponsive bladder cancer.

Detalimogene Shows 62% Response Rate in Bladder Cancer Trial

BySpencer Feldman

November 12th 2025

Image of people.

Experts Discuss Next Steps in Perioperative Bladder Cancer Treatment

ByDr. Joshua K. Sabari,Dr. Petros Grivas ,Chandler H. Park, MD

November 11th 2025

Dr. Minetta Liu

Signatera Guides Bladder Cancer Treatment After Surgery

BySpencer Feldman

November 11th 2025

Image of folks

Experts Discuss New Advances in Bladder Cancer Following ESMO 2025

ByDr. Petros Grivas ,Dr. Joshua K. Sabari,Dr. Chandler Park

November 10th 2025

Trending on CURE

FDA Approves First Interchangeable Biosimilar to Perjeta in HER2+ Breast Cancer

Experts Highlight Notable Advances in Colorectal Cancer at 2025 ESMO

Living With Purpose After a Metastatic Diagnosis

Shared Loss Leads to Lifelong Friendship in Rare Cancer Caregiving

Cancer Experts Share Emerging Treatments Patients Should Know in 2026

© 2025 MJH Life Sciences^®

All rights reserved.